Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19 CAR T Cells for Relapsed/Refractory CLL or Indolent B Cell Lymphoma
NCT00466531Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Mar 2007
- Primary completion
- Dec 2026
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of Vadacabtagene leraleucel, tisagenlecleucel in chronic lymphocytic leukemia (CLL), indolent B-cell lymphoma, sponsored by Memorial Sloan Kettering Cancer Center. Started Mar 2007; status: active, not recruiting.
02
Drugs
Vadacabtagene leraleuceltisagenlecleucel
03
Conditions
chronic lymphocytic leukemia (CLL)indolent B-cell lymphoma
Beyond the preview
Go deeper on NCT00466531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00466531.